Company profile: Animas
1.1 - Company Overview
Company description
- Provider of external insulin pumps for people with diabetes, designing, developing, manufacturing, and selling these devices. Believed to be the second-largest supplier in the U.S. by new pump placements. Introduced the R1000 in July 2000 and expects to begin shipping its third-generation pump.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Animas
Kaleido
HQ: The Netherlands
Website
- Description: Provider of wearable insulin pump solutions for diabetes management, including the Kaleido insulin pump delivering continuous fast-acting insulin over 24 hours with hourly adjustments, connecting via a tube and infusion set and wearable up to three days; the Kaleido with Diabeloop’s DBLG1 Hybrid Closed Loop using Dexcom G6 and a handheld device to auto-adjust dosing; and a starter kit with two reusable pumps, a handset, training and support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kaleido company profile →
Sigrid THx
HQ: Sweden
Website
- Description: Provider of ingested medical devices and platform technologies to lower blood sugar in prediabetics and newly diagnosed type 2 diabetics. Offerings include SiPore21 and the SiPore platform using engineered silica particles acting in the gut without absorption. Conducts clinical trials, including SiPore15 and SiPore21, with potential future indications in obesity, NASH, and infantile colic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sigrid THx company profile →
Diabeloop
HQ: France
Website
- Description: Provider of automated insulin delivery and diabetes management solutions, developing closed-loop systems to automate treatment of type 1 diabetes, including DBLG1, an algorithm-driven system; DBL-hu for highly unstable type 1 diabetes; and DBL-4pen, a smartphone app with an auto-learning algorithm linked to a connected insulin pen and CGM.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diabeloop company profile →
Generex
HQ: United States
Website
- Description: Provider of drug delivery systems and technologies for metabolic and immunological diseases, developing and commercializing these offerings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Generex company profile →
Diasome
HQ: United States
Website
- Description: Provider of insulin-based, liver-targeted diabetes therapeutics utilizing Hepatocyte Directed Vesicles (HDV) to enhance insulin delivery and reduce hypoglycemia risk. The company conducts multiple Phase 2 studies, including OPTI-2 and ISLE-1 Phase 2b trials, the Good to Great study, and an insulin pump crossover study, evaluating HDV added to rapid-acting insulin in patients with Type 1 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diasome company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Animas
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Animas
2.2 - Growth funds investing in similar companies to Animas
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Animas
4.2 - Public trading comparable groups for Animas
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →